FDA Head Says Marijuana Has ‘Benefit In Medical Conditions,’ But Trump Administration Also Concerned About ‘Side Effects’

OG article by Kyle Jaeger

February 13, 2026

FDA Commissioner Marty Makary stated that the Trump administration recognizes marijuana’s medical benefits for certain conditions while remaining deeply concerned about youth use and associated side effects. In a Fox Business interview, Makary emphasized the need to protect adolescents from high-potency THC products, noting a dramatic increase in teen vaping prior to the current administration.

Makary highlighted that modern marijuana is far stronger than in past decades and linked heavy use in adolescents to later psychosis diagnoses, fatigue, impaired learning, and reduced judgment. He also referenced cannabis hyperemesis syndrome as a significant side effect.

At the same time, Makary stressed the administration’s commitment to preserving and advancing medical access, particularly for patients with chronic or terminal conditions such as cancer. He cited the ongoing effort to reschedule marijuana from Schedule I to Schedule III under the Controlled Substances Act as evidence of this balanced approach.

President Trump issued an executive order in December directing Attorney General Pam Bondi to complete the rescheduling process expeditiously, though recent updates on progress remain limited. The DEA has confirmed the appeal process is still pending. Makary also noted prior warnings about cardiac risks and psychosis linked to certain cannabinoid products, underscoring the administration’s focus on both therapeutic potential and public health risks.